Cargando…

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin

Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahey, Catherine C., Nebhan, Caroline A., York, Sally, Davis, Nancy B., Hurley, Paula J., Gordetsky, Jennifer B., Schaffer, Kerry R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671469/
https://www.ncbi.nlm.nih.gov/pubmed/38003302
http://dx.doi.org/10.3390/ijms242216109
_version_ 1785140164219109376
author Fahey, Catherine C.
Nebhan, Caroline A.
York, Sally
Davis, Nancy B.
Hurley, Paula J.
Gordetsky, Jennifer B.
Schaffer, Kerry R.
author_facet Fahey, Catherine C.
Nebhan, Caroline A.
York, Sally
Davis, Nancy B.
Hurley, Paula J.
Gordetsky, Jennifer B.
Schaffer, Kerry R.
author_sort Fahey, Catherine C.
collection PubMed
description Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients.
format Online
Article
Text
id pubmed-10671469
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106714692023-11-09 Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin Fahey, Catherine C. Nebhan, Caroline A. York, Sally Davis, Nancy B. Hurley, Paula J. Gordetsky, Jennifer B. Schaffer, Kerry R. Int J Mol Sci Case Report Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients. MDPI 2023-11-09 /pmc/articles/PMC10671469/ /pubmed/38003302 http://dx.doi.org/10.3390/ijms242216109 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Fahey, Catherine C.
Nebhan, Caroline A.
York, Sally
Davis, Nancy B.
Hurley, Paula J.
Gordetsky, Jennifer B.
Schaffer, Kerry R.
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
title Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
title_full Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
title_fullStr Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
title_full_unstemmed Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
title_short Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
title_sort metastatic penile squamous cell carcinoma responsive to enfortumab vedotin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671469/
https://www.ncbi.nlm.nih.gov/pubmed/38003302
http://dx.doi.org/10.3390/ijms242216109
work_keys_str_mv AT faheycatherinec metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin
AT nebhancarolinea metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin
AT yorksally metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin
AT davisnancyb metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin
AT hurleypaulaj metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin
AT gordetskyjenniferb metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin
AT schafferkerryr metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin